arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

IDEXX LABORATORIES INC /DE

IDXX
$706.67 ▲ +30.77 (+4.55%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
73 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
86
Health
Excellent
Bullish
auto_awesome

Analytical Summary

IDEXX LABORATORIES INC /DE shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $55.7B
Dividend Yield —
Revenue Growth 9.9% ↗
Op. Margin 33.1% ↘
ROIC 14.7% ↘
FCF / Share $5.34 ↗
Trailing P/E 175.8x
Price / Book 29.8x
FCF Yield 0.8%
Debt / Equity 0.16
info Valuation on last close. End-of-day price, Nov 9, 2026.

73-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.21B
↑ +9.9% —
Net Income Profit after all expenses
$278.45M
↑ +14.7% —
Operating Margin Operating profit as % of sales
33.1%
↓ -5.3% 88th
FCF / Share Free cash flow per share
$5.34
↑ +30.7% —
Long-Term Debt Long-term obligations
$299.88M
— 0.0% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
87
Returns ↓
98
Financial Health →
79
Cash Quality ↑
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 6 days ago 19 years · 73 quarters